UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
15.25+0.32 (+2.14%)
At close: 4:00PM EDT
Sign in to post a message.
  • M
    Mr. Market
    544,000 shares traded during the whole day, and suddenly the volume jumped to over 1,000,000 shares in the last 10 minutes with strong buy 🤔🤔🤔
  • s
    sas
    Amazing company has no news to publish including CMS application, marketing and estimated revenue
  • M
    Michael
    The drug to drug interaction profile will simplify prescribing. The fear of addiction...will increase prescribing. The instant Vifor sales force will increase prescribing. The patient testimonials will increase prescribing. The lack of competition will increase prescribing. It's all good. No drug is perfect -- but this is the best chance I've seen for a pharma moonshot in a long time.
  • s
    sas
    Most of my undervalued stocks have increased. Cara is exception!!
  • s
    sas
    9.5+ million buy of additional stocks from Institutions and Vifor Pharm after FDA approval on 08/23/2021. Marketing and Phase 3 Oral AD clinical trial start initiation next catalyst. 6 days for shorters to cover their shorts!!
  • s
    sas
    Increase in short volume today. Short squeeze probability percentage is at peak now comparable to AMC.
  • W
    William H.
    Korsuva the first non addictive unregulated opioid in the world. No drug interactions as it is not metabolized in the liver. Acts like a steroid for pain, pruritus and inflammation but without the long term side effects of a steroid. Will be a very valuable drug in the years ahead.
  • W
    William H.
    The phase 2 dosing and effect trial of oral Korsuva to treat dermatitis actually was very encouraging for the following reasons: First atopic dermatitis is rated mild moderate or severe as to percent of the body covered by lessons not by the pruritus suffered by the patient. Mild to Moderate patients actually have more pruritus (itching) than severe patients. This group of mild to moderate met the trial end points in the trial.
    The severe patients lessons are better treated by a biologic drug that suppresses the immune system but with higher risk of side effects like Humira. During the trial Korsuva met it's end points for all patients(severe also) 75% of the time. Thus Pruritus is well controlled for all most of the time This information is discussed in the phase 2 conference call. The registration phase 3 trail for oral Korsuva should be successful based on the phase 2 results
  • B
    Brendan
    Vifor Pharma and Cara Therapeutics are in the process of submitting the required documentation to the U.S. Centers for Medicare and Medicaid Services (CMS) to ensure timely reimbursement and patient access to KORSUVA injection. Vifor Pharma expects to begin to market KORSUVA injection in Q1 2022 with reimbursement expected in H1 2022, subject to CMS timelines. That's a U.S government guaranteed revenue flow in coming years. Vifor would love to enjoy this revenue just for themselves instead of split profit sharing with Cara. Oral Corsuva would be just the extra cherry icing on the cake. I believe within 3-6 months Vifor will acquire CARA. It just makes complete sense for Vifor 100% buyout Cara instead profit-sharing arrangement they made. Vifor pharma, you were in love with Cara at first sight....we knew that. Now, it's time to get married, take your little gem 💍 home and live happily ever after!!
  • s
    sas
    200k plus in US three times per week can avail hemodialysis without fear of itching. Korsuva will be applied during dialysis and only approved drug works on source of the problem.
  • s
    sarath
    Rajesh,
    June 30th they has $207million in cash and marketable securities. Add another $50mm from Vifor they just received. They will be making revenues in 3/6 months on the new product. They do do not need a secondary offering. KEEP WORRYING!!!
  • s
    sas
    Approval not last good news. Increase in institutional buying to 81.4%, most are at average of 17.95. Vifor additional buy of 3.2 million, Average at 16.2. CMS application approval. Phase3 Dermatitis pruritus for low to Moderate start. Revenue updates.

    My average is at 17.6 will add more!!
  • H
    Harvey
    Steven A Cohen is invested in CARA. That says something!!
  • s
    sas
    From my personal experience I will tell you there is lot of difference when using prescribed medication and non-prescribed alternatives. My eczema become worse from mild when I tried all alternatives including over the counter creams and various antihistamine's . I am glad companies are researching and making effective medications for various itching issues including Cara therapeutics.
  • M
    Mike White
    Just for fun check out webr grill earnings 7 or 730! Wed
  • s
    sarath
    Recent Analyst Upgrades

    JP Morgan has a target price of $16, the lowest
    All the others, Piper, Stifel, Cantor, Wainwright, Canaccord, Needham and Jeffries, have target prices ranging from $23-$35
    CARA is way undervalued. These guys do detailed earnings models before assigning target prices/ratings.
  • s
    sas
    Non-steroid non-addictive drug to help people suffering from itching. Excited about marketing of injection and start of phase 3 oral trials
  • R
    Rajesh
    CARA is in quite period for 30 days. About 12 days have passed. As per agreement their partner will buy 250 millions $ worth shares at 20% premium.
  • J
    Jeffrey
    There will be no stock price appreciation until we see legit revenues . And when that happens things should be good .
    The market really is unimpressed with promise and hope and this is particularly true of biotech . They want to see dollars not dreams